Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7428 in Advanced or Recurrent Solid Tumors
NCT06816108Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Jul 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-7428 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 21 days and Adverse event up to 2 years. Started Apr 2025; status: active, not recruiting.
02
Drugs
ONO-7428
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06816108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816108.